This is reinforced by studies showing that drugs stimulating AMPK activity ameliorate hepatic steatosis [37,40], evidencing that AMPK is a therapeutic target for NAFLD. This evidence concerns the gene PRKAA2 and metabolic dysfunction-associated steatotic liver disease.